An acquired mutation in the cancer-causing gene PIK3CA can make blood vessel malformations in the brain worse, possibly explaining why these abnormal clusters sometimes rapidly increase in size and cause stroke or seizures, shows new research.
Research from the University of Pennsylvania and Duke University shows an acquired mutation in the cancer-causing gene PIK3CA can trigger uncontrolled growth in cerebral cavernous malformations often leading to strokes or seizures in those affected.
While the CRISPR-Cas9 gene editing system has become the poster child for innovation in synthetic biology, it has some major limitations. CRISPR-Cas9 can be programmed to find and cut specific pieces of DNA, but editing the DNA to create desired mutations requires tricking the cell into using a new piece of DNA to repair the break. This bait-and-switch can be complicated to orchestrate, and can even be toxic to cells because Cas9 often cuts unintended, off-target sites as well.
Alternative gene editing techniques called recombineering instead perform this bait-and-switch by introducing an alternate piece of DNA while a cell is replicating its genome, efficiently creating genetic mutations without breaking DNA. These methods are simple enough that they can be used in many cells at once to create complex pools of mutations for researchers to study. Figuring out what the effects of those mutations are, however, requires that each mutant be isolated, sequenced, and characterized: a time-consuming and impractical task.
Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard Medical School (HMS) have created a new gene editing tool called Retron Library Recombineering (RLR) that makes this task easier. RLR generates up to millions of mutations simultaneously, and “barcodes” mutant cells so that the entire pool can be screened at once, enabling massive amounts of data to be easily generated and analyzed. The achievement, which has been accomplished in bacterial cells, is described in a recent paper in PNAS.
Mitochondria are the energy suppliers of our body cells. These tiny cell components have their own genetic material, which triggers an inflammatory response when released into the interior of the cell. The reasons for the release are not yet known, but some cardiac and neurodegenerative diseases as well as the aging process are linked to the mitochondrial genome. Researchers at the Max Planck Institute for Biology of Aging and the CECAD Cluster of Excellence in Aging research have investigated the reasons for the release of mitochondrial genetic material and found a direct link to cellular metabolism: when the cell’s DNA building blocks are in short supply, mitochondria release their genetic material and trigger inflammation. The researchers hope to find new therapeutic approaches by influencing this metabolic pathway.
Our body needs energy—for every metabolic process, every movement and for breathing. This energy is produced in tiny components of our body cells, the so-called mitochondria. Unlike other cell components, mitochondria have their own genetic material, mitochondrial DNA. However, in certain situations, mitochondria release their DNA into the interior of the cell, causing a reaction from the cell’s own immune system and being associated with various diseases as well as the aging process. The reasons for the release of mitochondrial DNA are not yet known.
But the biotech industry has argued that much of gene-editing simply accelerates processes that occur naturally, and that GMO-style regulation would shackle efforts to develop sustainable crops or advance research into human disease.
The European Commission launched a review of EU rules on genetically modified organisms (GMOs) on Thursday, opening the door to a possible loosening of restrictions for plants resulting from gene-editing technology.
Prompted by a 2018 ruling from the European Union’s top court that techniques to alter the genome of an organism should be governed by existing EU rules on GMOs, the Commission concluded that its 2001 legislation was “not fit for purpose”.
Gene-editing technology targets specific genes within an organism to promote certain characteristics or curb others, while genetic modification involves transferring a gene from one kind of organism to another.
O,.o What a cure for cancer! o.o
Researchers are leveraging the messenger RNA (mRNA) technology used to develop the Pfizer-BioNTech and Moderna COVID-19 vaccines for possible treatments for a range of other diseases, including HIV and cancer.
This has long been thought possible with mRNA technology, but infectious diseases were something of the low-hanging fruit, and the COVID-19 pandemic drove the innovations.
MRNA technology is a way of exploiting the body’s own genetic blueprints. Traditional vaccines used either living or dead viruses to train the immune system to recognize viruses the next time they encounter them. The COVID-19 mRNA vaccines instead use the genetic code for a piece of the virus—the spike protein—and cause the body to generate the spike proteins, which trains the immune system to recognize the virus.
Why not add a light switch instead?
This month, a team from the University of California, San Francisco (UCSF) reimagined CRISPR to do just that. Rather than directly acting on genes—irrevocably dicing away or swapping genetic letters— the new CRISPR variant targets the biological machinery that naturally turns genes on or off.
Translation? CRISPR can now “flip a light switch” to control genes—without ever touching them directly. It gets better. The new tool, CRISPRoff, can cause a gene to stay silent for hundreds of generations, even when its host cells morph from stem cells into more mature cells, such as neurons. Once the “sleeping beauty” genes are ready to wake up, a complementary tool, CRISPRon, flips the light switch back on.
Cryopreservation, or the long-term storage of biomaterials at ultralow temperatures, has been used across cell types and species. However, until now, the practical cryopreservation of the fruit fly (Drosophila melanogaster)—which is crucial to genetics research and critical to scientific breakthroughs benefiting human health—has not been available.
“To keep alive the ever-increasing number of fruit flies with unique genotypes that aid in these breakthroughs, some 160000 different flies, laboratories and stock centers engage in the costly and frequent transfer of adults to fresh food, risking contamination and genetic drift,” said Li Zhan, a postdoctoral associate with the University of Minnesota College of Science and Engineering and the Center for Advanced Technologies for the Preservation of Biological Systems (ATP-Bio).
In new research published in Nature Communications, a University of Minnesota team has developed a first-of-its-kind method that cryopreserves fruit fly embryos so they can be successfully recovered and developed into adult insects. This method optimizes embryo permeabilization and age, cryoprotectant agent composition, different phases of nitrogen (liquid vs. slush), and post-cryopreservation embryo culture methods.
CEO of Turn. Bio at 3:40 talking about getting product to market in a few years rather than a decade.
#ERA #sebastiano #turnbio #krammer #stanford #healthspan #aging #longevity.
Ms. Anja Krammer, CEO of Turn Biotechnologies talks about the initial targets for ERA, the time line for clinical trials and FDA approval.
Turn Bio was co-founded by Dr. Vittorio Sebastiano to develop and market the Epigenetic Reprogramming of Aging technology that came out of his lab in Stanford University.
Ms. Krammer is a veteran of F500 healthcare and technology companies and co-founder of three Silicon Valley start ups. She is an entrepreneur who has built biotech, pharmaceutical and consumer businesses by assembling high-performance, results-driven teams and a counsellor to multiple enterprises, who has served on boards of public and private companies, industry organizations and foundation.
Turn Biotechnologies, Inc.
https://www.turn.bio/
Paper on ERA Technology.
https://www.nature.com/articles/s41467-020-15174-3
More papers by Dr. Sebastiano.
http://med.stanford.edu/sebastiano/publications.html
The only thing bad about Star Trek was they made the Borg evil.
Emerging technologies have unprecedented potential to solve some of the world’s most pressing issues. Among the most powerful — and controversial — is the gene-editing tech, CRISPR-Cas9, which will improve agricultural yields, cure genetic disorders, and eradicate infectious diseases like malaria. But CRISPR and other disruptive technologies, like brain-machine interfaces and artificial intelligence, also pose complex philosophical and ethical questions. Perhaps no one is better acquainted with these questions than Peter Diamandis, founder of the XPRIZE Foundation and co-founder of Singularity University and Human Longevity Inc. In this session, Peter will give a state of the union on the near future and explore the profound ethical implications we will face in the ongoing technological revolution.
This talk was recorded at Summit LA19.
Interested in attending Summit events? Apply to attend : https://summit.co/apply.
Connect with us:
https://www.youtube.com/channel/UCMGlHWuKnlWVoY5GXpXTYzg.
http://www.summit.co.
http://www.instagram.com/summit.
http://fb.com/summit.
Tweets by Summit
